AQR Capital Management LLC bought a new stake in shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK – Free Report) in the 2nd quarter, HoldingsChannel.com reports. The fund bought 10,164 shares of the company’s stock, valued at approximately $75,000.
Other institutional investors have also recently made changes to their positions in the company. Squarepoint Ops LLC acquired a new stake in Outlook Therapeutics in the 2nd quarter worth about $232,000. Great Point Partners LLC lifted its position in shares of Outlook Therapeutics by 15.0% in the second quarter. Great Point Partners LLC now owns 1,701,510 shares of the company’s stock valued at $12,557,000 after acquiring an additional 221,510 shares in the last quarter. LVW Advisors LLC acquired a new stake in shares of Outlook Therapeutics in the second quarter valued at approximately $352,000. Finally, Rosalind Advisors Inc. increased its holdings in shares of Outlook Therapeutics by 44.3% in the second quarter. Rosalind Advisors Inc. now owns 450,000 shares of the company’s stock valued at $3,321,000 after purchasing an additional 138,225 shares during the last quarter. 11.20% of the stock is owned by hedge funds and other institutional investors.
Outlook Therapeutics Stock Up 3.3 %
Shares of NASDAQ OTLK opened at $5.31 on Friday. The business has a 50-day moving average of $6.40 and a two-hundred day moving average of $7.40. Outlook Therapeutics, Inc. has a 1 year low of $4.61 and a 1 year high of $18.00.
Analyst Upgrades and Downgrades
Several equities research analysts have issued reports on the company. Chardan Capital reissued a “buy” rating and set a $53.00 target price on shares of Outlook Therapeutics in a research note on Friday, August 16th. Ascendiant Capital Markets cut their target price on Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd. BTIG Research restated a “buy” rating and set a $50.00 price target on shares of Outlook Therapeutics in a research report on Friday. Finally, HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Outlook Therapeutics in a research report on Thursday, August 15th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $48.20.
Read Our Latest Stock Report on Outlook Therapeutics
Insiders Place Their Bets
In other news, CFO Lawrence A. Kenyon bought 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 26th. The stock was purchased at an average cost of $5.69 per share, with a total value of $28,450.00. Following the transaction, the chief financial officer now directly owns 5,946 shares in the company, valued at $33,832.74. This trade represents a 500.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 3.40% of the stock is owned by company insiders.
Outlook Therapeutics Company Profile
Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Recommended Stories
- Five stocks we like better than Outlook Therapeutics
- Election Stocks: How Elections Affect the Stock Market
- Survey Reveals: America’s Most Coveted Businesses in 2024
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- What is the S&P 500 and How It is Distinct from Other Indexes
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Want to see what other hedge funds are holding OTLK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Outlook Therapeutics, Inc. (NASDAQ:OTLK – Free Report).
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.